Paul B Watkins MD
Howard Q Ferguson Distinguished Professor, Director, Institute for Drug Safety Sciences, University of North Carolina at Chapel Hill
Join to View Full Profile
101 Manning DrChapel Hill, NC 27599
Phone+1 919-226-3140
Fax+1 919-226-3150
Dr. Watkins is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- I am a board certified gastroenterologist specializing in liver diseases, particularly drug-induced liver injury.
Education & Training
University of MichiganFellowship, Gastroenterology, 1982 - 1985
New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 1979 - 1982
Weill Cornell MedicineClass of 1979
Certifications & Licensure
NC State Medical License 1999 - 2027
MI State Medical License 1986 - 2005
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Gastroenterology
Awards, Honors, & Recognition
- Agilent Thought Leader Award 2015
- Rawls Palmer Innovation in Medicine Award 2015
- Elected Fellow of the AASLD American Association for the Study of Liver Diseases, 2013
Clinical Trials
Publications & Presentations
PubMed
- 4 citationsAssessment of liver injury potential of investigational medicines in drug development.Naga Chalasani, Paul H Hayashi, Debra Luffer-Atlas, Arie Regev, Paul B Watkins
Hepatology. 2025-02-25 - Blood toxicogenomics reveals potential biomarkers for management of idiosyncratic drug-induced liver injury.Rachel J Church, Benedict Anchang, Brian D Bennett, Pierre R Bushel, Paul B Watkins
Frontiers in Genetics. 2025-01-01 - 2 citationsTolvaptan safety in autosomal-dominant polycystic kidney disease; a focus on idiosyncratic drug-induced liver injury liabilities.Sean Hammond, Xiaoli Meng, Jane Barber, Merrie Mosedale, Amy Chadwick
Toxicological Sciences. 2025-01-01
Journal Articles
- Review Post Screen Advancing Nonclinical Innovation and Safety in Pharmaceutical TestingMichael N Liebman, Elizabeth J Baker, Paul B Watkins, ScienceDirect
- A Rapid Method to Estimate Hepatocyte Loss Due to Drug‐Induced Liver InjuryPaul Watkins, MD, Clinical Pharmacology & Therapeutics
- Can BSEP Inhibition Testing in Drug Discovery and Development Reduce Liver Injury Risk? ‐ an International Transporter Consortium PerspectivePaul Watkins, MD, Clinical Pharmacology & Therapeutics
Press Mentions
- First Approved Cancer Treatment for TGCT Included DILIsym Simulations in FDA ReviewOctober 27th, 2020
FDA Review of Approved Drug, Ubrogepant, Included DILIsym SimulationsSeptember 2nd, 2020
U.S. FDA Renews Annual DILIsym Software LicensesMay 6th, 2020
Grant Support
- University of North Carolina Clinical Center for DILINUNIV OF NORTH CAROLINA CHAPEL HILL2003–2028
- University of North Carolina Clinical Center for DILINUNIV OF NORTH CAROLINA CHAPEL HILL2003–2028
- Research Triangle Center of Excellence in Regulatory Science and InnovationUNIV OF NORTH CAROLINA CHAPEL HILL2023–2026
- Research Triangle Center of Excellence in Regulatory Science and InnovationUNIV OF NORTH CAROLINA CHAPEL HILL2023–2026
- Research Triangle Center of Excellence in Regulatory Science and InnovationUNIV OF NORTH CAROLINA CHAPEL HILL2023–2026
Professional Memberships
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
